Understanding retinal degeneration for the purpose of optogenetic vision restoration

Brief plain language background 

Sight loss caused by many retinal degenerations is often permanent because the photoreceptors in the eye that are responsible for detecting light gradually stop working and die. Once these cells are lost, current treatments can’t restore vision. However, new scientific approaches, such as optogenetics, aim to reprogram the remaining cells in the eye to respond to light using special light-sensitive proteins. This project builds on previous work that successfully used this technique to restore basic vision in blind mice. We now want to understand the conditions under which this kind of therapy works best, such as when in the disease process to apply it and how the remaining cells behave as the eye degenerates. We are also testing whether supporting treatments like antioxidants or vitamin-like compounds could improve the restored vision. Together, these approaches may lead to more effective treatments for people affected by severe sight loss. 

What problem/knowledge gap does it help address 

Currently, there is no cure for most inherited retinal diseases that lead to the commonest case of blindness in working age population. While optogenetic therapy can restore some vision by making the surviving cells in the retina sensitive to light, we still don’t fully understand how well this works as the disease progresses. We do not currently understand whether these remaining cells are still biologically able to support light responses, the best time to apply therapy, and whether the treatment slows down ongoing damage to the retina. It’s also unclear if supplementing protective compounds like antioxidants can improve the quality of restored vision. This project aims to fill those knowledge gaps. By doing so, it will provide the scientific foundations needed to guide how and when future treatments are given and how to improve their effects, leading to better and more predictable outcomes for patients living with retinal degeneration. 

Aim of the project 

To understand how changes in the retina during disease affect the success of light-restoring therapies and whether adding supportive treatments can improve outcomes. The goal is to inform when and how to use these therapies most effectively in people with sight loss due to retinal degeneration. 

Potential impact on people with sight loss 

This research aims to improve treatments for people losing their vision due to retinal degenerative diseases. By understanding how and when to use light-activating (optogenetic) therapy, and whether combining it with protective treatments helps, we hope to restore useful vision even after major vision loss. These findings could guide future clinical trials and improve outcomes for patients. If successful, this approach could begin benefiting patients within 5–10 years through more effective and longer-lasting vision restoration therapies. This gives real hope to those currently without treatment options for advanced retinal degeneration.